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Hospitalizations, and Ventricular Arrhythmias
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Francisco Leyva, MD
Background-—Predicting clinical outcomes after cardiac resynchronization therapy (CRT) and its optimization remain a challenge.
We sought to determine whether pre- and postimplantation QRS area (QRSarea) predict clinical outcomes after CRT.
Methods and Results-—In this retrospective study, QRSarea, derived from pre- and postimplantation vectorcardiography, were
assessed in relation to the primary end point of cardiac mortality after CRT with or without deﬁbrillation. Other end points included
total mortality, total mortality or heart failure (HF) hospitalization, total mortality or major adverse cardiac events, and the
arrhythmic end point of sudden cardiac death or ventricular arrhythmias with or without a shock. In patients (n=380, age
72.012.4 years, 68.7% male) undergoing CRT over 7.7 years (median follow-up: 3.8 years [interquartile range 2.3–5.3]),
preimplantation QRSarea ≥102 lVs predicted cardiac mortality (HR: 0.36; P<0.001), independent of QRS duration (QRSd) and
morphology (P<0.001). A QRSarea reduction ≥45 lVs after CRT predicted cardiac mortality (HR: 0.19), total mortality (HR: 0.50),
total mortality or heart failure hospitalization (HR: 0.44), total mortality or major adverse cardiac events (HR: 0.43) (all P<0.001)
and the arrhythmic end point (HR: 0.26; P<0.001). A concomitant reduction in QRSarea and QRSd was associated with the lowest
risk of cardiac mortality and the arrhythmic end point (both HR: 0.12, P<0.001).
Conclusions-—Pre-implantation QRSarea, derived from vectorcardiography, was superior to QRSd and QRS morphology in predicting
cardiac mortality after CRT. A postimplant reduction in both QRSarea and QRSd was associated with the best outcomes, including
the arrhythmic end point. ( J Am Heart Assoc. 2019;8:e013539. DOI: 10.1161/JAHA.119.013539.)
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C ardiac resynchronization therapy (CRT) is an establishedtreatment for patients with heart failure (HF), impaired
left ventricular (LV) function, and a wide QRS complex.1 As
with any medical therapy, its treatment effect is variable.
“Nonresponder” rates range from 9% to 68%, depending on
the criteria used to deﬁne response.2 Although no medical
therapy can be expected to be 100% effective, there is a
consensus view that response to CRT can be improved.3
Manifold imaging studies explored mechanical dyssyn-
chrony in relation to patient selection and optimization but,
ultimately, no single measure of mechanical dyssynchrony has
been adopted by clinical guidelines.4 In this context, we
should consider CRT is an electrical treatment and that its
substrate should be electrical rather than mechanical. In this
respect, QRS duration (QRSd) has been adopted as a
surrogate of electrical dyssynchrony in randomized, controlled
trials,1 and a reduction in QRSd has been shown to predict
better long-term outcomes after CRT.5,6
Evidence has recently emerged in support of vectorcardio-
graphy in the ﬁeld of CRT. In this respect, QRS area (QRSarea)
has been shown to correlate with LV lateral wall activation
time,7 the maximum rate of rise of LV pressure (DLV dP/
dtmax),
8,9 and LV reverse remodeling10 after CRT. Crucially,
pre-implantation QRSarea has also been shown to be superior
to pre-implantation QRSd and QRS morphology in predicting
total mortality after CRT.11,12
Although QRSarea and QRSd duration relate to depolariza-
tion in a global sense, QRSarea also yields the dominant axis of
the activation sequence.13 Given that the objective of CRT is
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to make depolarization more synchronous, both the pacing
location and timing between LV and right ventricular pacing
can be used to manipulate activation sequence. In this study,
we explored pre- and postimplantation QRSarea and QRSd in
relation to long-term cardiac mortality, HF hospitalization, and
major adverse cardiac events (MACEs) after CRT.
Methods
Patients referred for CRT implantation at the University
Hospitals Birmingham, Queen Elizabeth, United Kingdom,
were retrospectively evaluated. The study was approved by
the local Ethics Committee and local Clinical Audit Depart-
ment, both of which waived patient consent on the basis that
all study tests and interventions had already been undertaken.
The study conforms with the Declaration of Helsinki.
Study Population
Patients undergoing CRT implantation from November 2011
to June 2018 were identiﬁed. Implantation practice adhered to
the United Kingdom’s National Institute of Clinical Excellence
guidelines, which before 2007 recommended CRT with
deﬁbrillation (CRFT-D) only in the context of secondary
prevention. After 2014, National Institute of Clinical Excel-
lence recommended cardiac resynchronization therapy with
deﬁbrillation rather than CRT-pacing in nonischemic car-
diomyopathy.14
Inclusion criteria were the following: indications for CRT
according to National Institute of Clinical Excellence guidance
and availability of a digitizable 12-lead ECG before and after
implantation. Exclusion criteria were the following: subjects
with technically unsuitable ECGs and patients with congenital
heart disease.
Device Therapy
Device implantation was undertaken using standard transve-
nous techniques with patients under local anesthesia and
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Figure 1. Vectorcardiography in cardiac resynchronization therapy. The vectorcardiogram displays the various features of the ECG, such as
the QRS complex, in the form of “loops,” which are determined from vectors representing successive, instantaneous mean electrical forces
throughout the cardiac cycle. A, A representation of the 3 vectorcardiogram leads (X, Y, and Z), according to Frank’s orthogonal lead system. B,
Two-dimensional vector loops in the frontal (X-Y leads), sagittal (Y-Z leads), and transverse (X-Z leads) planes from a patient with a left bundle
branch block. The QRSarea is calculated as the integral sum of the area bound by the QRS complex and the isoelectric baseline in each
vectorcardiogram lead (X, Y, and Z).
Clinical Perspective
What Is New?
• Pre-implantation QRSarea was superior to QRSd and QRS
morphology in predicting cardiac and total mortality after
cardiac resynchronization therapy.
• Concomitant reductions in QRSarea and QRSd after cardiac
resynchronization therapy were associated with the best
survival and the lowest risk of heart failure hospitalization,
major adverse cardiac eventsaswell as ventricular arrhythmias.
What Are the Clinical Implications?
• Reductions in QRSarea and QRSd could be a focus for
optimization after cardiac resynchronization therapy implan-
tation.
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Table 1. Characteristics of the Study Group According to Pre-Implantation QRS Area
All
QRSarea
≥102 lVs
QRSarea
<102 lVs P Value
N 380 197 183
Age, y 7212.4 72.212.9 71.911.7 0.832
Sex (male), n (%) 261 (68.68) 119 (60.41) 142 (77.6) <0.001
NYHA class, n (%)
I 26 (7.34) 17 (9.34) 9 (5.23) 0.190
II 87 (24.58) 46 (25.27) 41 (23.84)
III 225 (63.56) 114 (62.64) 111 (64.53)
IV 16 (4.52) 5 (2.75) 11 (6.4)
Cause, n (%)
Ischemic 182 (47.89) 74 (37.56) 108 (59.02) <0.001
Nonischemic 198 (52.11) 123 (62.44) 75 (40.98)
Comorbidities, n (%)
Diabetes mellitus 89 (23.42) 41 (20.81) 48 (26.23) 0.213
Hypertension 106 (27.89) 57 (28.93) 49 (26.78) 0.639
CABG 64 (16.84) 23 (11.68) 41 (22.4) 0.005
Device type, n (%)
CRT-D 209 (55.15) 94 (47.96) 115 (62.84) 0.004
CRT-P 170 (44.85) 102 (52.04) 68 (37.16)
Upgrades, n (%)
Pacemaker to CRT-D 39 (47.56) 23 (43.40) 16 (55.17) 0.307
Pacemaker to CRT-P 43 (52.44) 30 (56.60) 13 (44.83)
CRT-D indication*
Primary prevention 166 (79.4) 76 (80.9) 90 (78.3) 0.645
Secondary prevention 43 (20.6) 18 (19.1) 25 (21.7)
LVEF, % 25.89.9 25.59.7 26.010.3 0.633
Medication, n (%)
ACEI/ARA 337 (89.63) 173 (88.72) 164 (90.61) 0.548
b-Blocker 277 (73.67) 140 (71.79) 137 (75.69) 0.391
MRA 167 (44.41) 80 (41.03) 87 (48.07) 0.170
ECG variables
Sinus rhythm, n (%) 269 (70.79) 152 (77.16) 117 (63.93) 0.005
AF/flutter, n (%) 111 (29.21) 45 (22.84) 66 (36.07)
PR interval, ms 192.554.7 181.639.8 207.567.5 <0.001
QRSd, ms 153.522.7 163.920.4 142.219.5 <0.001
QRS <150 ms, n (%) 169 (44.47) 45 (22.84) 124 (67.76) <0.001
LBBB, n (%) 239 (62.89) 151 (76.65) 88 (48.09) <0.001
RBBB, n (%) 33 (8.68) 1 (0.51) 32 (17.49) <0.001
NICD, n (%) 59 (15.53) 5 (2.54) 54 (29.51) <0.001
RV-paced, n (%) 49 (12.89) 40 (20.30) 9 (4.92) <0.001
Vectorcardiography variable
QRSarea, lVs 113.456.5 156.941.7 66.622.7 <0.001
ACEI indicates angiotensin receptor converting enzyme inhibitor; AF, atrial ﬁbrillation; ARA, angiotensin receptor antagonist; CABG, coronary artery bypass graft; CRT-D, cardiac
resynchronization therapy with deﬁbrillation; CRT-P, cardiac resynchronization therapy-pacing; LBBB, left bundle branch block; MRA, mineralocorticoid receptor antagonist; LVEF, left
ventricular ejection fraction; NICD, nonspeciﬁc conduction delay; NYHA, New York Heart Association; QRSarea, QRS area; QRSd, QRS duration; RBBB, right bundle branch block; RV, right
ventricular.
*Expressed as a percentage of CRT-D devices.
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intravenous sedation. Following implantation, patients were
followed up in combined cardiac device therapy/HF clinics.
Devices were programmed according to physician discretion.
Generally, backup atrial pacing was set at 60 beats/min, and
the pacing mode was set to DDDR. The atrioventricular delay
was set at 90 ms and the interventricular delay to between 0
and 20 ms (LV ﬁrst). In patients in permanent atrial
ﬁbrillation, right ventricular and LV leads were deployed, a
CRT generator was implanted, and devices were programmed
to a ventricular triggered mode. Atrioventricular junction
ablation was undertaken according to physicians’ discretion.
Targeted echocardiographic optimization was only undertaken
in symptomatic nonresponders.
Lead positions
The anteroposterior, as well as the left anterior and right
anterior oblique ﬂuoroscopic views from coronary sinus
venography taken at the time of implantation were used
retrospectively to assess the LV lead tip position, as
previously described.15 All LV lead positions were assessed
retrospectively by an experienced implanter (F.L.) who was
blinded to clinical outcome data.
ECG
Pre-implantation, standard supine 12-lead ECGs (25 mm/s,
10 mm/mV) were used for analysis. A left bundle branch
block (LBBB) was deﬁned as a QRSd >120 ms, rS or QS in
lead V1, notched or slurred R-waves in leads I, aVL, V5 or V6,
with absent q waves in leads V5 and V6.
16 We used this
deﬁnition rather than “strict” Strauss criteria, as the latter is
not predictive of clinical outcomes after CRT.12 Right bundle
branch block was deﬁned as a QRS ≥120 ms, with a wide,
positive R-wave deﬂection in lead V1 and a slurred S wave in
leads I and V6. A nonspeciﬁc intraventricular conduction delay
was deﬁned as nonpaced QRS >120 ms not ﬁtting these
criteria. Postimplantation ECGs were undertaken within
3 months after implantation.
Vectorcardiography
Standard 12-lead ECGs were ﬁrst converted to an Extensible
Markup Language (XML) format using ECGScan (AMPS LLC,
New York, USA), a commercially available program approved
by the US Food and Drug Administration. A custom-made
program was used for generation of 2 vectorcardiographies
according to Frank’s orthogonal lead system using the Kors
transformation. The latter was used given previous evidence
that it is superior to other vectorcardiography transformations
in predicting clinical outcomes after CRT.12 The start and end
of the QRS complex were deﬁned semi-automatically using
digital calipers at 200% magniﬁcation. For paced rhythms, the
onset and end of the QRS complex was measured manually,
excluding the pacing spike. Digitization of ECGs and gener-
ation of vectorcardiographies were undertaken by a single
investigator (O.O.) who was blinded to clinical outcomes
Table 2. Clinical Outcomes
All
Pre-CRT Post-CRT
QRSarea
≥102 lVs
QRSarea
<102 lVs
QRSarea Reduction
≥45 lVs
QRSarea Reduction
<45 lVs
N 380 197 183 177 203
Mortality end points
Cardiac mortality 70 (18.4) 21 (10.7) 49 (26.8) 11 (6.21) 59 (29.1)
Sudden cardiac death* 5 (7.14) 1 (4.76) 4 (8.16) 0 5 (8.47)
Death from pump failure* 63 (90.0) 19 (90.5) 44 (89.8) 10 (90.9) 53 (89.8)
Total mortality 135 (35.5) 55 (27.9) 80 (43.7) 42 (23.7) 93 (45.8)
Total mortality or HF hospitalization 165 (43.4) 66 (33.5) 99 (54.1) 53 (29.9) 112 (55.2)
Total mortality or hospitalization for MACE 185 (48.7) 74 (37.6) 111 (60.7) 59 (33.3) 126 (62.1)
Ventricular arrhythmic events
All VT/VF 32 (8.42) 12 (6.09) 20 (10.9) 7 (3.95) 25 (12.3)
VT/VF treated with ATP only 6 (15.8) 4 (2.03) 2 (1.09) 3 (1.69) 3 (1.48)
Appropriate shocks (with or without ATP) 19 (5.0) 7 (3.55) 14 (7.65) 2 (1.13) 17 (8.37)
Inappropriate shocks 1 (0.26) 0 1 (0.5) 0 1 (0.5)
Clinical outcomes, expressed as n (%), according to pre-implantation QRS area (QRSarea) and postimplantation change in QRSarea. ATP indicates antitachycardia pacing; CRT, cardiac
resynchronization therapy; HF, heart failure; MACE, major adverse cardiac events; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
*Expressed as a percentage of cardiac deaths.
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collected by another investigator (A.Z.). The QRSarea
was calculated as the integral between the ventricular
deﬂection curve and the isoelectric line in each the 3
orthogonal leads (X, Y, and Z), according to the formula:
ðX2area þ Y2area þ Z2areaÞ1=2 (Figure 1).
End points
The primary end point was cardiac mortality, which included
cardiac transplantation or implantation of a ventricular assist
device. The secondary end point was total mortality. Ancillary
end points included total mortality or unplanned HF hospital-
ization; total mortality or unplanned hospitalization for MACE;
and the combined end point of sudden cardiac death,
ventricular tachycardia, ventricular ﬁbrillation, or shock.
MACE included unplanned hospitalization for HF, myocardial
infarction, acute coronary syndrome, ventricular arrhythmias,
and atrial ﬁbrillation. A HF hospitalization was deﬁned as an
unplanned admission related to worsening dyspnea, in
association with peripheral edema, pulmonary edema on
chest radiography, and requirement for intravenous diuretic
therapy. Device-treated arrhythmias (appropriately treated
with shocks or antitachycardia pacing) not leading to an
unplanned hospitalization were not regarded as a hospitaliza-
tion for MACE. Stroke and pulmonary embolism were not
regarded as MACE. In composite end points, the ﬁrst event
was included in statistical analyses. Mortality data were
collected through medical record and cross-checked with a
national mortality database. Data were collected retrospec-
tively from medical records and entered into an electronic
database every 6 months by investigators who were blinded
to clinical and imaging data. Events were adjudicated by
blinded investigators on a 6-monthly basis.
Mode of death
Sudden cardiac death was deﬁned as a natural, unexpected
death because of cardiac causes, heralded by an abrupt loss
of consciousness within 1 hour of the onset of acute
symptoms. Death from pump failure was deﬁned as “death
after a period of clinical deterioration in signs and symptoms
of HF despite medical treatment”.17
Statistical Analysis
Continuous variables are expressed as mean SD. Normality
was tested using the Shapiro–Wilk test. Comparisons
between normally distributed continuous variables were made
using the Student t test. Categorical variables were analyzed
using v2 tests. Receiver operating characteristic curves were
QRSd:    0.60
LBBB:     0.53
QRSarea : 0.71
AUC
ΔQRSd:    0.72
ΔQRSarea : 0.74
AUC
PRE-CRT POST-CRT
Figure 2. Receiver-operator characteristic curves. Graphs show areas under the receiver-operator characteristic curves (AUC) for QRSd, QRS
area, and QRS morphology (LBBB) in the whole cohort. AUC indicates area under the curve; CRT, cardiac resynchronization therapy; LBBB, left
bundle branch block.
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created to assess the predicted probabilities of ECG and
vectorcardiography variables in relation to cardiac mortality. A
10-fold cross-validation was used as the model validation
technique for assessing performance, and the average was
calculated over 10 repetitions. The measure with largest area
under the receiver operating characteristic (area under the
curve [AUC]) was used for subsequent analyses. The Liu
method was also applied to estimate nonparametrically the
optimal cutoffs for ECG and vectorcardiography measures.18
Kaplan–Meier curves and the log-rank test were used to
assess cumulative survival and Cox proportional hazard
models were used to assess relative risks. Proportionality
hypotheses were veriﬁed by visual examination of log
(survival) and Schoenfeld residuals. Variables reaching
P<0.10 as univariate predictors of cardiac mortality were
entered in multivariate models. Statistical analyses were
undertaken by a biostatistician (T.Q.) who did not partake in
data collection. The Stata15 (StataCorp, TX) statistical
package was used. The package “cvauroc” was used for
cross-validation of the areas under the receiver operating
characteristic curve, and package “cutpt” was used for
empirical estimation of optimal cutoffs. A 2-sided P<0.05
was considered statistically signiﬁcant.
Results
Baseline Characteristics
The analytic sample consisted of 380 patients. As shown in
Table 1, baseline characteristics were typical of a CRT
population (age 72.012.4 years [meanSD], 68.7% male)
with a left ventricular ejection fraction of 25.89.9% and a
Log Rank p < 0.001
HR 0.33 (95% CI: 0.19-0.57)
CARDIAC MORTALITY
TOTAL MORTALITY OR HF HOSPITALIZATION TOTAL MORTALITY OR MACE
TOTAL MORTALITY    
Log Rank p = 0.001
HR 0.50 (95% CI: 0.33-0.76)
Log Rank p < 0.001
HR 0.43 (95% CI: 0.28-0.65)
Log Rank p < 0.001
HR 0.39 (95% CI: 0.26-0.59)
QRSarea ≥ 102 μVs
QRSarea < 102 μVs
QRSarea ≥ 102 μVs
QRSarea < 102 μVs
QRSarea ≥ 102 μVs
QRSarea < 102 μVs
QRSarea ≥ 102 μVs
QRSarea < 102 μVs
Figure 3. Clinical outcomes according to pre-implantation QRS area. Kaplan–Meier survival curves for the various end points according to
precardiac resynchronization therapy QRSarea. Results of univariate Cox proportional hazard models are expressed in terms of hazard ratio (HR)
(95% CI). HF indicates heart failure; MACE, major adverse cardiac events.
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QRSd of 153.522.7 ms. The cutoff of pre-CRT QRSarea
derived from the Liu method was 102 lVs (86–119 lVs). The
QRSarea groups were well matched for age, New York Heart
Association class, diabetes mellitus and hypertension status,
upgrade status, left ventricular ejection fraction, and medica-
tion. In the QRSarea <102 lVs group, patients were more
likely to be male, to have ischemic cardiomyopathy or a
previous coronary artery bypass operation, and a greater
proportion received CRT with deﬁbrillation rather than CRT-
pacing.
Pre-CRT QRSarea
Over a median follow-up period of 3.8 years (interquartile
range 2.3–5.3), 135/380 (36%) patients died, 70/380 (18%)
from cardiac causes and 31/380 (8%) from noncardiac
causes (Table 2). The cause of death was unknown in 34/380
(9%).
The AUC for predicting cardiac mortality was higher for
QRSarea than for QRSd or QRS morphology (0.71, 0.60, and
0.53, respectively; P<0.001 for comparison) (Figure 2) and for
QRSd and QRS morphology combined (AUC: 0.66; P=0.002).
In Kaplan–Meier survival analyses, QRSarea ≥102 lVs was
associated with a lower cardiac mortality (P<0.001), total
mortality (P=0.001), total mortality or HF hospitalization, and
total mortality or MACE (both P<0.001) (Table 2 and
Figure 3). In univariable Cox proportional hazards analyses,
QRSarea predicted cardiac mortality, total mortality, total
mortality or HF hospitalization, and total mortality or MACE
(all P<0.001) (Table 3). In multivariate analyses, QRSarea (per
lVs) predicted cardiac mortality (adjusted hazard ratio [HR]:
0.99 [95% CI]: 0.98–0.99), independent of all baseline
variables, including QRSd and QRS morphology (Table 4).
Post-CRT QRSarea
The QRSarea decreased by 41.0 lVs (interquartile range: 79
to 4) after CRT (Figure 4). The cutoff of DQRSarea derived
from Liu method was 45 lVs ([60] to [31] lVs). As
shown in Table 5, the DQRSarea groups were well matched for
age, New York Heart Association class, hypertension and
diabetes mellitus status, device type, left ventricular ejection
fraction, and medical therapy (Table 5). A QRSarea reduction
≥45 lVs group had a lower proportion of men (P<0.001), and
most had nonischemic cardiomyopathy (P<0.001). As
expected from the DQRSarea grouping, there were signiﬁcant
differences in ECG and vectorcardiography variables.
Cardiac mortality was 11/177 (6.21%) in patients with
QRSarea reduction ≥45 lVs and 59/203 (29.1%) in patients
with QRSarea reduction <45 lVs. (Table 2). The AUC for
predicting cardiac mortality for DQRSarea and DQRSd were
similar (0.74 versus 0.72; P=0.425 for comparison) (Figure 2).Ta
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In Kaplan–Meier survival analyses, a QRSarea reduction
≥45 lVs was associated with a lower cardiac mortality, total
mortality, total mortality or HF hospitalization, and total
mortality or MACE, compared with a QRSarea reduction
<45 lVs (all P<0.001) (Figures 5 and 6). In univariate
analyses, a QRSarea reduction ≥45 lVs was a strong predictor
of cardiac mortality (HR: 0.19, 95% CI: 0.10–0.36), as well as
other end points (all P<0.001) (Table 3).
Interaction of DQRSarea and DQRSd
As shown in Figures 2 and 5, DQRSarea and DQRSd were
comparable predictors of cardiac mortality. In Cox propor-
tional hazard analyses, a signiﬁcant interaction between
DQRSarea and DQRSd emerged with respect to cardiac
mortality (HR: 0.12, 96% CI 0.06–0.26). A similar trend was
observed for total mortality, total mortality or HF hospitaliza-
tion, and total mortality or MACE (Figure 6).
Lead Positions
Most LV leads were deployed in a lateral or posterolateral
position (Table 5). As shown in Figure 7, there was consid-
erable interindividual variability in DQRSarea and DQRSd within
each LV lead position, but no signiﬁcant differences emerged
in DQRSarea or DQRSd between the different LV lead
positions.
Arrhythmic events
As shown in Table 3 and Figure 8, both QRSd and QRSarea
predicted the combined end point of sudden cardiac death,
ventricular tachycardia/ventricular ﬁbrillation or shock, but no
Table 4. Univariate and Multivariate Analysis of Pre-Implantation Variables in Relation to Cardiac Mortality
Univariate Multivariate
HR 95% CI P Value HR 95% CI P Value
Age, y 1.02 1.00 1.04 0.044 1.02 1.00 1.05 0.097
Sex (male) 2.25 1.21 4.19 0.011 1.57 0.80 3.07 0.186
NYHA class (I, II) 0.61 0.32 1.14 0.122
Ischemic cause 1.73 1.07 2.80 0.026 1.07 0.63 1.80 0.813
Comorbidities
Diabetes mellitus 2.08 1.28 3.38 0.003 1.56 0.95 2.58 0.081
Hypertension 1.25 0.76 2.08 0.380
CABG 1.46 0.83 2.54 0.187
CRT-D 0.79 0.49 1.26 0.327
Upgrades 1.18 0.67 2.09 0.564
LVEF (%) 0.98 0.96 1.01 0.141
Medication
ACEI/ARA 0.56 0.29 1.10 0.092 0.63 0.31 1.27 0.196
b-Blocker 0.80 0.48 1.33 0.389
MRA 1.24 0.78 1.98 0.371
ECG variables
AF/flutter 1.62 1.01 2.62 0.047 1.03 0.60 1.76 0.925
PR interval, ms 1.00 1.00 1.01 0.153
LBBB 0.79 0.49 1.27 0.331
RBBB 2.50 1.34 4.65 0.004 0.92 0.42 2.02 0.831
RV-paced 0.56 0.22 1.38 0.207
NICD 1.08 0.58 2.01 0.806
QRSd, ms 0.99 0.98 1.00 0.075 1.01 0.99 1.02 0.219
QRSarea, lVs 0.99 0.98 0.99 <0.001 0.98 0.98 0.99 <0.001
ACEI indicates angiotensin receptor converting enzyme inhibitor; AF, atrial ﬁbrillation; ARA, angiotensin receptor antagonist; CABG, coronary artery bypass graft; CRT-D, cardiac
resynchronization therapy with deﬁbrillation; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NICD,
nonspeciﬁc intraventricular conduction delay; NYHA, New York Heart Association; QRSarea, QRS area; QRSd, QRS duration; RBBB, right bundle branch block; RV, right ventricular.
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such relationship was observed for QRS morphology. A
QRSarea reduction ≥45 lVs (HR: 0.26, 95% CI 0.11–0.58) and
QRSd reduction (HR: 0.33, 95% CI 0.17–0.67) predicted this
combined end point. Concomitant reductions in QRSarea and
QRSd were associated with the lowest risk of the arrhythmic
end point (HR: 0.12, 95% CI 0.04–0.41).
Discussion
This is the ﬁrst study to explore both pre- and postimplan-
tation QRSarea in relation to long-term, cause-speciﬁc mortal-
ity, as well as long-term HF hospitalization, MACE, and
ventricular arrhythmias after CRT. Several ﬁndings have
emerged. First, pre-implantation QRSarea was superior to
QRSd and QRS morphology in predicting cardiac mortality
after CRT. Second, a QRSarea reduction after CRT was
associated with favorable outcomes, independent of baseline
QRSd or QRS morphology. Third, the best outcomes after CRT
were observed in patients exhibiting concomitant reductions
in QRSarea and QRSd.
Pre-CRT QRSarea
This study provides an external validation of the ﬁndings of 2
observational studies showing that QRSarea is superior to QRSd
and QRS morphology in predicting total mortality after CRT.11,12
We found that QRSarea (<102 lVs) predicted total mortality, with
an AUC of 0.71, which is higher than theAUC of 0.61 identiﬁed by
van Stipdonk et al using a cutoff of 109 lVs.11 Emerek et al
found that a QRSarea ≤95 lVs was associated with a higher total
mortality than a QRSarea >95 lVs, with an unadjusted HR of 2.11
(P<0.001).12 Using a cutoff of 102 lVs, we have found an
unadjusted HR of 1.73 (P=0.002) for total mortality and 2.77 for
cardiac mortality (P<0.001).
Previous studies on QRSarea
11,12 did not address cause-
speciﬁc mortality and only 1 year follow-up data were
provided with respect to HF hospitalization.11 We found that,
in addition to predicting total mortality, QRSarea predicted
cardiac mortality, total mortality or HF hospitalization, and
total mortality or MACE. The relation between a high QRSarea
and better clinical outcomes after CRT is not unexpected,
because QRS area correlates with electrical dyssynchrony,8
the natural substrate of CRT.
Post-CRT DQRSarea
In an acute hemodynamic study of 25 patients with LBBB, De
Pooter et al showed that DQRSarea correlated with DLV dP/
dtmax.
8 This is consistent with our ﬁnding that a reduction in
QRSarea was associated with a lower cardiac mortality, as well
as other end points. While De Pooter et al8 found that
DQRSarea after CRT was a stronger correlate of DLV dP/dtmax
than DQRSd, we found that both DQRSd and DQRSarea were
comparable in predicting long-term clinical outcomes. Impor-
tantly, the combination of DQRSd and DQRSarea had additive
effects in predicting cardiac mortality: patients who exhibited
reductions in both variables experienced the best outcomes
after CRT, whereas patients who did not exhibit reductions in
either experienced the worst outcomes.
QRSd
Randomized, controlled trials of CRT19,20 adopted a QRSd
≥120 ms as an indication for CRT. In COMPANION (Compar-
ison of Medical Therapy, Pacing, and Deﬁbrillation in Heart
Failure), patients without LBBB and those with QRSd ≤147 ms
did not derive a beneﬁt.19 Similarly, in the MADIT-CRT
(Multicenter Automatic Deﬁbrillator Implantation Trial–
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Figure 4. Postimplantation changes in QRS area and QRS duration. Box-and-whisker plots of QRS area
(left) and QRS duration (QRSd) (right) before and after CRT implantation. The horizontal line denotes the
median, whereas the lower and upper limits of the box denote the ﬁrst and third quartiles. The limits of the
vertical bar denote maximum and minimum. CRT indicates cardiac resynchronization therapy.
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Cardiac Resynchronization Therapy) trial, patients with a
QRSd <150 ms derived no survival beneﬁt from CRT.21,22 In
the present study, we found that a QRSd ≥150 ms was
associated with a lower cardiac mortality, compared with a
QRSd <150 ms. The ability of QRSd to predict cardiac
mortality, however, was relatively weak (AUC: 0.60).
Meta-analyses of observational studies have shown an
inconsistent relationship between post-CRT DQRSd23,24 and
“clinical response.” In these meta-analyses, however, “clinical
response” was deﬁned in terms of symptoms, echocardio-
graphic variables, and/or hard end points, assuming that
these are identical, interchangeable measures. On the other
hand, studies focusing on hard end points do indeed support a
relationship between a QRSd reduction and better outcomes
after CRT. The REVERSE (Resynchronization Reverses Remod-
eling in Systolic Left Ventricular Dysfunction) study, the only
randomized controlled trial to address DQRSd after CRT,
explored acute DQRSd in the CRT-treated group in relation to
the primary end point of the clinical composite score, as well
as LV reverse remodeling.25 Although not designed to address
hard end points, REVERSE reported an association between
DQRSd and total mortality or HF hospitalization over a
relatively short follow-up (12 months in North America and for
24 months in Europe) on univariate analyses, but not in a
multivariate model that corrected for baseline QRSd. Impor-
tantly, however, the CRT-treated group in REVERSE only had 4
deaths over 24 months, raising the possible play of statistical
underpowering. In contrast, in an observational study, Appert
et al showed that a lack of postoperative QRSd reduction was
independently associated with an increased risk of total
mortality over a median follow-up period of 48 months.6 In a
similar study, Jastrzebski et al showed that a QRSd reduction
predicted death from any cause or urgent heart transplanta-
tion and death from any cause/urgent heart transplantation
or hospital admission for HF over an average follow-up period
of 46 months.5 In the present study, in which 135 deaths
occurred over a median follow-up of 3.8 years, a QRSd
Table 5. Characteristics of the Study Group According to
Post-Implantation Change in QRS Area
QRSarea Reduction
≥45 lVs
QRSarea Reduction
<45 lVs P Value
N 177 203
Age, y 72.113.1 7211.7 0.979
Sex (male), n (%) 103 (58.19) 158 (77.83) <0.001
NYHA class, n (%)
I 14 (8.48) 12 (6.35) 0.322
II 36 (21.82) 51 (26.98)
III 110 (66.67) 115 (60.85)
IV 5 (3.03) 11 (5.82)
Cause, n (%)
Ischemic 67 (37.85) 115 (56.65) <0.001
Nonischemic 110 (62.15) 88 (43.35)
Comorbidities, n (%)
Diabetes mellitus 44 (24.86) 45 (22.17) 0.537
Hypertension 50 (28.25) 56 (27.59) 0.886
CABG 17 (9.6) 47 (23.15) <0.001
Device type, n (%)
CRT-D 90 (51.14) 119 (58.62) 0.144
CRT-P 86 (48.86) 84 (41.38)
Upgrades, n (%)
Pacemaker to CRT-D 14 (35) 25 (59.52) 0.026
Pacemaker to CRT-P 26 (65) 17 (40.48)
LVEF 25.39.1 26.210.7 0.429
Medication, n (%)
ACEI/ARA 154 (88) 183 (91.04) 0.334
b-Blocker 125 (71.43) 152 (75.62) 0.357
MRA 82 (46.86) 85 (42.29) 0.374
ECG variables
Sinus rhythm, n (%) 139 (78.53) 130 (64.04) 0.002
AF/flutter, n (%) 38 (21.47) 73 (35.96)
PR interval, ms 178.334.5 208.867.6 <0.001
QRSd, ms 162.120.6 145.921.8 <0.001
LBBB, n (%) 134 (75.71) 105 (51.72) <0.001
RBBB, n (%) 2 (1.13) 31 (15.27) <0.001
NICD, n (%) 10 (5.65) 49 (24.14) <0.001
RV-paced, n (%) 31 (17.51) 18 (8.87) 0.012
Vectorcardiography variable
QRSarea, lVs 153.947.5 78.136.3 <0.001
Circumferential lead positions
Anterior 6 (3.39) 8 (3.94) 0.498
Anterolateral 28 (15.8) 37 (18.2)
Lateral 73 (41.2) 86 (42.3)
Posterolateral 24 (13.6) 16 (9.03)
Posterior 46 (26.0) 56 (27.6)
Continued
Table 5. Continued
QRSarea Reduction
≥45 lVs
QRSarea Reduction
<45 lVs P Value
Longitudinal lead positions
Basal 19 (10.7) 12 (5.91) 0.249
Mid 99 (55.9) 121 (59.6)
Apical 59 (33.3) 70 (34.5)
ACEI indicates angiotensin receptor converting enzyme inhibitor; AF, atrial ﬁbrillation;
ARA, angiotensin receptor antagonist; CABG, coronary artery bypass graft; CRT-D,
cardiac resynchronization therapy with deﬁbrillation; CRT-P, cardiac resynchronization
therapy-pacing; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist; NICD, nonspeciﬁc intraventricular
conduction delay; NYHA, New York Heart Association; QRSarea, QRS area; QRSd, QRS
duration; RBBB, right bundle branch block; RV, right ventricular.
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QRSd
Log Rank p < 0.001
HR: 0.19 (95% CI: 0.10-0.36)
Log Rank p < 0.001
HR: 0.23 (95% CI: 0.14-0.39)
Log Rank p < 0.001
HR: 0.12 (95% C.I. 0.06-0.26) *
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Figure 5. QRS area and QRS duration in relation to cardiac mortality. Kaplan–Meier survival
curves and univariate HR and (95% CI for QRS area (QRSarea) and QRS duration (QRSd) in
relation to cardiac mortality. *Refers to the interaction between changes in QRSarea and
QRSd after CRT. HR indicates hazard ratios.
DOI: 10.1161/JAHA.119.013539 Journal of the American Heart Association 11
QRS Area and CRT Okafor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
reduction below baseline predicted cardiac mortality, total
mortality, total mortality or HF hospitalization, and total
mortality or MACE.
QRS Morphology
Observational studies26,27 as well as large registries28 and
subanalyses of randomized, controlled trials19,22,25,29 have shown
that patients with a LBBB morphology derive the most beneﬁt
from CRT. While some studies have suggested that a LBBB
deﬁned using “strict” criteria, with notching and/or slurring of the
QRS complex, is associated with a better left ventricular ejection
fraction response to CRT,10,27 this is not a consistent ﬁnding.30,31
Moreover, Emerek et al found that “strict” (Strauss) criteria of
LBBB was not predictive of clinical outcomes after CRT.12 In the
present study, a conventionally deﬁned LBBB did not predict
cardiac mortality after CRT (AUC: 0.53).
Lead Position
We have observed a considerable interindividual variability in
QRSarea at a given LV lead position. In this regard, De Pooter
et al also found a similar interindividual variability in QRSarea
in CRT recipients with a LBBB.8 Crucially, they also found that
QRSarea and the acute hemodynamic response to CRT in a
given patient could be improved by changing the LV lead
position. Together, these ﬁndings make the case for opti-
mization of QRSarea in CRT recipients. To date, however, no
studies have prospectively explored this issue.
Arrhythmic events
Several studies have suggested that QRSd predicts sudden
cardiac death.32,33 In contrast, no studies have explored
QRSarea or DQRSarea in relation to sudden cardiac death or
ventricular tachycardia/ventricular ﬁbrillation. Although pre-
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Figure 6. Secondary clinical end points according to changes in QRS area and QRS duration. Kaplan–Meier survival curves for the various end
points according to postcardiac resynchronization therapy reductions in QRSarea (≥45 lVs) QRS duration (QRSd; to any value below baseline).
HF indicates heart failure; MACE, major adverse cardiac events.
DOI: 10.1161/JAHA.119.013539 Journal of the American Heart Association 12
QRS Area and CRT Okafor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
implantation QRSarea did not predict this end point, its
reduction was associated with a 74% reduction in the end
point. Moreover, concomitant with QRSarea reduction, a QRd
reduction was associated with an 88% lower risk of the
combined end point. This novel ﬁnding, which was not
anticipated, could speculatively relate to a greater dispersion
of depolarization in relation to arrhythmic events. The physio-
logical basis for this empirical ﬁnding requires further study.
Clinical Perspectives
Attention has recently focused on ECG imaging using body
surface mapping as a tool for identifying electrical dyssyn-
chrony and to predict response to CRT.34,35 Although there is
a proof-of-principle and encouraging clinical data to support
the use of this technique in CRT, it requires specialized
acquisition. Importantly, data on body surface mapping in
relation to long-term outcomes after CRT are lacking. In
contrast, QRSarea can be readily derived from the standard 12-
lead ECG and crucially, is now known to predict long-term
clinical outcomes. The role of QRSarea in patient selection and
CRT optimization requires further investigation.
Limitations
This study has all the limitations of an observational study.
Although we have corrected for potential confounders using
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statistical means, unobserved variables may have contributed to
outcomes. Importantly, vectorcardiographies were derived retro-
spectively from 12-lead ECGs undertaken before implantation.
Inconsistencies in electrode position could conceivably inﬂuence
vectorcardiography analysis.36 Notwithstanding, all ECGs were
acquired by trained cardiac technicians using a standardized
operating procedure in routine clinical practice. Consequently,
our results should be generalizable to a “real-world” environment.
Unfortunately, we did not systematically collect data on device
programming. In this respect, variable programming at implan-
tation and follow-up could account for variations in ECG and
vectorcardiography variables, as well as outcomes. Although the
AUCs for pre-implant QRSarea andDQRSarea did not exceed 0.74,
these values are comparable to those found in other studies11 and
exceed the AUCs for QRSd and LBBB.
Conclusions
Pre-implantation QRSarea was superior to QRSd and QRS
morphology in predicting clinical outcomes after CRT. A
concomitant reduction in QRSd and QRSarea after CRT was
associated with the lowest risk of cardiac and total mortality,
as well as ventricular arrhythmias. These ﬁndings add support
for the use of QRSarea and QRSd in the risk stratiﬁcation and
optimization of CRT recipients.
Sources of Funding
Okafor was supported by an unrestricted educational grant
from Medtronic Plc.
Disclosures
None.
References
1. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J
Am Coll Cardiol. 2014;64:1047–1058.
2. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA,
Leon AR, Oshinski JN. Agreement is poor among current criteria used to deﬁne
response to cardiac resynchronization therapy. Circulation. 2010;121:1985–
1991.
3. Auricchio A, Prinzen FW. Enhancing response in the cardiac resynchronization
therapy patient: the 3B perspective-bench, bits, and bedside. JACC Clin
Electrophysiol. 2017;3:1203–1219.
4. Chung E, Leon A, Tavazzi L, Sun J, Nihoyannopoulos P, Merlino J, Abraham W,
Guio S, Leclerq C, Bax J, Yu C-M, Gorcsan J III, Sutton M, De Sutter J, Murillo J.
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation.
2008;117:2608–2616.
5. Jastrzebski M, Baranchuk A, Fijorek K, Kisiel R, Kukla P, Sondej T, Czarnecka D.
Cardiac resynchronization therapy-induced acute shortening of QRS duration
predicts long-term mortality only in patients with left bundle branch block.
Europace. 2019;21:281–289.
6. Appert L, Menet A, Altes A, Ennezat PV, Bardet-Bouchery H, Binda C, Guyomar
Y, Delelis F, Castel AL, Le Gofﬁc C, Guerbaai RA, Graux P, Tribouilloy C,
Marechaux S. Clinical signiﬁcance of electromechanical dyssynchrony and
QRS narrowing in patients with heart failure receiving cardiac resynchroniza-
tion therapy. Can J Cardiol. 2019;35:27–34.
7. Maﬁ Rad M, Wijntjens GW, Engels EB, Blaauw Y, Luermans JG, Pison L, Crijns HJ,
Prinzen FW, Vernooy K. Vectorcardiographic QRS area identiﬁes delayed left
ventricular lateral wall activation determined by electroanatomic mapping in
candidates for cardiac resynchronization therapy. Heart Rhythm. 2016;13:217–225.
8. De Pooter JAN, El Haddad M, De Buyzere M, Aranda HA, Cornelussen R,
Stegemann B, Rinaldi CA, Sterlinski M, Sokal A, Francis DP, Jordaens LUC,
Stroobandt RX, Van Heuverswyn F, Timmermans F. Biventricular paced QRS
area predicts acute hemodynamic CRT response better than QRS duration or
QRS amplitudes. J Cardiovasc Electrophysiol. 2017;28:192–200.
9. Engels EB, Strik M, van Middendorp LB, Kuiper M, Vernooy K, Prinzen FW.
Prediction of optimal cardiac resynchronization by vectors extracted from
electrograms in dyssynchronous canine hearts. J Cardiovasc Electrophysiol.
2017;28:944–951.
10. van Deursen CJM, Vernooy K, Dudink E, Bergfeldt L, Crijns HJGM, Prinzen FW,
Wecke L. Vectorcardiographic QRS area as a novel predictor of response to
cardiac resynchronization therapy. J Electrocardiol. 2015;48:45–52.
11. van Stipdonk AMW, Ter Horst I, Kloosterman M, Engels EB, Rienstra M, Crijns
H, Vos MA, van Gelder IC, Prinzen FW, Meine M, Maass AH, Vernooy K. QRS
area is a strong determinant of outcome in cardiac resynchronization therapy.
Circ Arrhythm Electrophysiol. 2018;11:e006497.
12. Emerek K, Friedman DJ, Sørensen PL, Hansen SM, Larsen JM, Risum N,
Thøgersen AM, Graff C, Kisslo J, Søgaard P, Atwater BD. Vectorcardiographic
QRS area is associated with long-term outcome after cardiac resynchroniza-
tion therapy. Heart Rhythm. 2018;16:213–219.
13. Lux R, Urie P, Burgess M, Abildskov L. Variability of the body surface
distributions of QRS, ST-T and QRST deﬂection areas with varied activation
sequence in dogs. Cardiovasc Res. 1980;14:607–612.
14. National Institute of Health and Care Excellence. NICE technology appraisal
[TA 314]: implantable cardioverter deﬁbrillators and cardiac resynchronisation
therapy for arrhythmias and heart failure (review of TA95 and TA120). 2014.
London, United Kingdom. Available at: https://www.nice.org.uk/guidance/ta
314. Accessed February 1, 2019.
15. Leyva F, Zegard A, Taylor RJ, Foley PWX, Umar F, Patel K, Panting J, van Dam P,
Prinzen FW, Marshall H, Qiu T. Long-term outcomes of cardiac resynchro-
nization therapy using apical versus nonapical left ventricular pacing. J Am
Heart Assoc. 2018;7:e008508. DOI: 10.1161/JAHA.117.008508.
16. Linde C, Abraham WT, Gold MR, Daubert C. Cardiac resynchronization therapy
in asymptomatic or mildly symptomatic heart failure patients in relation to
etiology: results from the REVERSE (REsynchronization reVErses Remodeling
in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol.
2010;56:1826–1831.
17. Rockman HA, Juneau C, Chatterjee K, Rouleau JL. Long-term predictors of
sudden and low output death in chronic congestive heart failure secondary to
coronary artery disease. Am J Cardiol. 1989;64:1344–1348.
18. Liu X. Classiﬁcation accuracy and cut point selection. Stat Med.
2012;31:2676–2686.
19. Bristow M, Saxon L, Boehmer J, Krueger S, Kass D, De Marco T, Carson P,
DiCarlo L, DeMets D, White B. Cardiac-resynchronization therapy with or
without an implantable deﬁbrillator in advanced chronic heart failure. N Engl J
Med. 2004;350:2140–2150.
20. Cleland J, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L,
Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in
heart failure. N Engl J Med. 2005;352:1539–1549.
21. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM,
Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba
W. Cardiac-resynchronization therapy for the prevention of heart-failure
events. N Engl J Med. 2009;361:1329–1338.
22. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D,
Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E,
Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ; Madit-CRT
Investigators. Effectiveness of cardiac resynchronization therapy by QRS
morphology in the multicenter automatic deﬁbrillator implantation trial-cardiac
resynchronization therapy (MADIT-CRT). Circulation. 2011;123: 1061–1072.
23. Kashani A, Barold SS. Signiﬁcance of QRS complex duration in patients with
heart failure. J Am Coll Cardiol. 2005;46:2183–2192.
24. Bryant AR, Wilton SB, Lai MP, Exner DV. Association between QRS duration
and outcome with cardiac resynchronization therapy: a systematic review and
meta-analysis. J Electrocardiol. 2013;46:147–155.
25. Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, St John Sutton
M, Daubert JC. Effect of QRS duration and morphology on cardiac resynchro-
nization therapy outcomes in mild heart failure: results from the Resynchro-
nization Reverses Remodeling in Systolic Left Ventricular Dysfunction
(REVERSE) study. Circulation. 2012;126:822–829.
DOI: 10.1161/JAHA.119.013539 Journal of the American Heart Association 15
QRS Area and CRT Okafor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
26. Sweeney MO, van Bommel RJ, Schalij MJ, Borleffs CJ, Hellkamp AS, Bax JJ.
Analysis of ventricular activation using surface electrocardiography to predict
left ventricular reverse volumetric remodeling during cardiac resynchronization
therapy. Circulation. 2010;121:626–634.
27. Tian Y, Zhang P, Li X, Gao Y, Zhu T, Wang L, Li D, Wang J, Yuan C, Guo J. True
complete left bundle branch block morphology strongly predicts good
response to cardiac resynchronization therapy. Europace. 2013;15:1499–
1506.
28. Bilchick Kenneth C, Kamath S, DiMarco John P, Stukenborg George J. Bundle-
branch block morphology and other predictors of outcome after cardiac
resynchronization therapy in Medicare patients. Circulation. 2010;122:2022–
2030.
29. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser
SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchro-
nization-Deﬁbrillation for Ambulatory Heart Failure Trial I. Cardiac-resynchro-
nization therapy for mild-to-moderate heart failure. N Engl J Med.
2010;363:2385–2395.
30. Bertaglia E, Migliore F, Baritussio A, De Simone A, Reggiani A, Pecora D,
D’Onofrio A, Rapacciuolo A, Savarese G, Pierantozzi A, Marenna B, Ruffa F,
Campari M, Malacrida M, Stabile G. Stricter criteria for left bundle branch
block diagnosis do not improve response to CRT. Pacing Clin Electrophysiol.
2017;40:850–856.
31. Caputo ML, van Stipdonk A, Illner A, D’Ambrosio G, Regoli F, Conte G, Moccetti
T, Klersy C, Prinzen FW, Vernooy K, Auricchio A. The deﬁnition of left bundle
branch block inﬂuences the response to cardiac resynchronization therapy. Int
J Cardiol. 2018;269:165–169.
32. Kurl S, Makikallio TH, Rautaharju P, Kiviniemi V, Laukkanen JA. Duration of
QRS complex in resting electrocardiogram is a predictor of sudden cardiac
death in men. Circulation. 2012;125:2588–2594.
33. Morin DP, Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS, Kjeldsen SE,
Dahlof B, John M, Devereux RB, Okin PM. QRS duration predicts sudden
cardiac death in hypertensive patients undergoing intensive medical therapy:
the LIFE study. Eur Heart J. 2009;30:2908–2914.
34. Ploux S, Eschalier R, Whinnett ZI, Lumens J, Derval N, Sacher F, Hocini M, Jais
P, Dubois R, Ritter P, Haissaguerre M, Wilkoff BL, Francis DP, Bordachar P.
Electrical dyssynchrony induced by biventricular pacing: implications for
patient selection and therapy improvement. Heart Rhythm. 2015;12:782–791.
35. Gage RM, Curtin AE, Burns KV, Ghosh S, Gillberg JM, Bank AJ. Changes in
electrical dyssynchrony by body surface mapping predict left ventricular
remodeling in patients with cardiac resynchronization therapy. Heart Rhythm.
2017;14:392–399.
36. Tomlinson DR, Bashir Y, Betts TR, Rajappan K. Accuracy of manual QRS duration
assessment: its importance in patient selection for cardiac resynchronization
and implantable cardioverter deﬁbrillator therapy. Europace. 2009;11:638–642.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.119.013539 Journal of the American Heart Association 16
QRS Area and CRT Okafor et al
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
